Adagene Inc. presented new data at AACR 2026 showing that muzastotug, combined with other therapies, significantly improved response rates in difficult cancers. In hepatocellular carcinoma (HCC), the triple combo of muzastotug, atezolizumab, and bevacizumab achieved a 66.7% overall response rate, outperforming the control arm's 32.5%. In microsatellite stable colorectal cancer (MSS CRC), the triple combo with pembrolizumab and fruquintinib showed dose-dependent responses up to 40% ORR. The therapy demonstrated a favorable safety profile and potential to enhance current immunotherapies without increased toxicity. These promising results support further development of muzastotug as a backbone treatment for multiple tumor types.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Rotork PLC has accepted a £4.1 billion takeover bid from Swiss engineering group ABB, offering shareholders 506p per share, a 73% premium over the previous closing price. The acquisition will enhance ABB's industrial automation business by adding Rot...
Alexandria Real Estate Equities (ARE) is struggling with oversupply and vacancy rates exceeding 30% in key life science markets like Boston, San Francisco, and San Diego. This has caused an 80% decline in its stock price from its peak. The company's ...
ASML Holdings has raised its 2026 revenue guidance midpoint from €38 billion to €44 billion and increased its gross margin midpoint from 52% to 55%, reflecting strong growth prospects. The analyst maintains a Buy rating and raises the price target fr...
Labcorp is considered a buy due to its effective rollup strategy in a fragmented lab testing industry, driving steady and predictable growth. Automation is reducing operational costs, helping to counteract healthcare pricing pressures. The company no...
